Recent Updates
Recently added Catalysts
OCS Positive Sentiment Score: 75/100

Oculis to Present at Upcoming September Investor Conferences

Thursday, August 29, 2024 2 min read
Key Takeaway: Oculis Holding AG (Nasdaq: OCS) announced its management will attend and present at several upcoming investor conferences in September 2024, including events hosted by Wells Fargo and H.C. Wainwright. Oculis aims to enhance investor relations and highlight its innovative pipeline, which includes products targeting diabetic macular edema and dry eye disease. Interested investors are encouraged to contact their representatives for one-on-one meetings. The presentations will be accessible on the Oculis website.

Market Sentiment Analysis

POSITIVE FACTORS

  • Oculis presents at multiple investor conferences, increasing visibility.
  • Management showcases innovative pipeline of eye care products.
  • Company aims to enhance patient health and quality of life.

Full Press Release Details

ZUG, Switzerland, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis’ management will be attending and presenting at the following upcoming investor conferences:
Wells Fargo Healthcare Conference 2024
Event dates: September 4-6, 2024
Location: Encore Boston Harbor, Boston, MA
H.C. Wainwright 26th Annual Global Investment Conference
Event dates: September 9-11, 2024
Company Presentation by Riad Sherif, MD, Chief Executive Officer on September 11 at 9:30 am ET
Location: Lotte New York Palace Hotel, NY, NY
Baird Global Healthcare Conference 2024
Event dates: September 10-11, 2024
Fireside Chat with Sylvia Cheung, Chief Financial Officer on September 10 at 9:05 am ET
Location: InterContinental New York Barclay, NY, NY
The Company will be available for one-on-one meetings during the conferences. Interested investors should contact their respective representative at the sponsoring institutions to request meetings. A link to access company presentation, when available, will be posted to Oculis website on the Events & Presentation page under the Investors & Media section.
Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical eye drop candidate for diabetic macular edema (DME) and for the treatment of inflammation and pain following cataract surgery; OCS-02 (licaminlimab), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED) and for non-infectious anterior uveitis; and OCS-05, a neuroprotective candidate for acute optic neuritis (AON). Headquartered in Switzerland and with operations in the U.S. and Iceland, Oculis’ goal is to improve the health and quality of life of patients worldwide. The company is led by an experienced management team with a successful track record and is supported by leading international healthcare investors.
For more information, please visit: www.oculis.com
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com
Investor & Media Relations
cdavis@lifesciadvisors.com

Frequently Asked Questions

When will Oculis present at the Wells Fargo Healthcare Conference?

Oculis will present at the Wells Fargo Healthcare Conference from September 4-6, 2024.

Who will present at the H.C. Wainwright Conference?

Riad Sherif, MD, CEO of Oculis, will present on September 11 at 9:30 am ET.

What is OCS-01 used for?

OCS-01 is a topical eye drop for diabetic macular edema and post-cataract surgery.

Where is Oculis headquartered?

Oculis is headquartered in Zug, Switzerland, with operations in the U.S. and Iceland.

How can investors schedule meetings with Oculis?

Interested investors should contact their representatives at the sponsoring institutions.

Tags: OCS Viatris Investor Conferences Healthcare Oculis eye care investor conferences healthcare
Last updated: Aug 29, 2024